key: cord-0719488-ffm5fww3
authors: Liu, Yongyu; Bi, Lijun; Chen, Yu; Wang, Yaguo; Fleming, Joy; Yu, Yanhong; Gu, Ye; Liu, Chang; Fan, Lichao; Wang, Xiaodan; Cheng, Moxin
title: Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity
date: 2020-03-16
journal: nan
DOI: 10.1101/2020.03.10.20033795
sha: a92029e6e42de51a3b93e503d757e27b6909b991
doc_id: 719488
cord_uid: ffm5fww3

Importance: Risk factors associated with COVID-19, the viral pneumonia originating in Wuhan, China, in Dec 2019, require clarification so that medical resources can be prioritized for those at highest risk of severe COVID-19 complications. Infection with M. tuberculosis (MTB), the pathogen that causes TB and latently infects ~25% of the global population, may be a risk factor for SARS-CoV-2 infection and severe COVID-19 pneumonia. Objective: To determine if latent or active TB increase susceptibility to SARS-COV-19 infection and disease severity, and lead to more rapid development of COVID-19 pneumonia. Design: An observational case-control study of 36 confirmed COVID-19 cases from Shenyang, China, conducted in Feb 2020. Final date of follow-up: Feb 29, 2020. Cases were grouped according to COVID-19 pneumonia severity (mild/moderate, severe/critical), and MTB infection status compared. Comparisons were made with MTB infection data from another case-control study on bacterial/viral pneumonia at Shenyang Chest Hospital. Setting: Multi-center study involving three primary care hospitals in Shenyang, China. Participants: 86 suspected COVID-19 cases from participating primary-care hospitals in Shenyang. All 36 SARS-CoV-2 +ve cases (based on RT-PCR assay) were included. Disease severity was assessed using the Diagnostic and Treatment Guidelines of the National Health Commission of China (v6). Mean age, 47 years (range: 25-79), gender ratio, 1:1. Exposures: Confirmed COVID-19 pneumonia. Interferon-gamma Release Assays (IGRA) were performed using peripheral blood to determine MTB infection. Main Outcome and Measures: Epidemiological, demographic, clinical, radiological, and laboratory data were collected. Comparison of MTB infection status between patients with mild/moderate and severe/critical COVID-19 pneumonia. Results: Mean age of 36 COVID-19 patients: 47 (range: 25-79); M/F: 18/18; Wuhan/Hubei connection: 42%. Mild/moderate cases: 27 (75%); severe/critical: 9 (25%). MTB infection (IGRA+ve): 13 cases (36.11%), including 7 of 9 severe/critical cases. MTB infection rate: higher in COVID-19 (36.11%) than bacterial pneumonia (20%; p=0.0047) and viral pneumonia patients (16.13%; p=0.024). MTB infection more common than other co-morbidities (36.11% vs diabetes: 25%; hypertension: 22.2%; coronary heart disease: 8.33%; COPD: 5.56%). MTB co-infection linked with disease severity (severe/critical 78% vs mild/moderate cases 22%; p=0.0049), and rate of disease progression: infection to development of symptoms (MTB+SARS-CoV-2: 6.5+/-4.2 days vs SARS-COV-2: 8.9+/-5.2 days; p=0.073); from symptom development to diagnosed as severe (MTB+SARS-CoV-2: 3.4+/-2.0 days vs SARS-COV-2: 7.5+/-0.5 days; p=0.075). Conclusions and Relevance: MTB infection likely increases susceptibility to SARS-CoV-2, and increases COVID-19 severity, but this requires validation in a larger study. MTB infection status of COVID-19 patients should be checked routinely at hospital admission.

COVID-19, the viral pneumonia that emerged in Wuhan, China, in December 2019, has spread throughout China and to 85 other countries. To date (Mar 5, 2020), there have been 95,333 confirmed cases worldwide and 3282 deaths 1 . COVID-19 poses a major threat to global health and was declared a 'public health emergency of international concern' by the WHO on 30 Jan 2020 2 .

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 16, 2020. . https://doi.org/10.1101/2020.03.10.20033795 doi: medRxiv preprint While most SARS-CoV-2 infections in the general population result in only mild symptoms, individuals with underlying comorbidities, particularly the elderly, are more vulnerable to SARS-CoV-2 infection and require additional care [3] [4] [5] . It is important to gain a clear picture of risk factors associated with this new viral respiratory infection in order to allocate appropriate medical resources to prevent the development of severe or critical forms of COVID-19 in those considered to be at higher risk. Here, we consider the possibility that infection with Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB), the top cause of death due to an infectious disease, may predispose to SARS-CoV infection and the more rapid development of symptoms and severe COVID-19 pneumonia.

86 people with COVID-19 symptoms presented at hospitals in Shenyang, China, between Jan 26, 2020 and Feb 15, 2020 and were tested for SARS-CoV-2 infection. COVID is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Guidelines of the National Health Commission of China (v5) 9 ) were included in the study.

Demographic data are shown in Supplementary Table 1. These studies were approved by the Ethics Committee of Shenyang Chest Hospital, and informed written consent was obtained from each of the study participants.

Throat swabs, blood and sputum were collected from suspected COVID-19 patients and sent for SARS-CoV-2 testing using a real-time reverse-transcription polymerase chain reaction assay 6,7 at the Shenyang Disease Control Center.

IFN- IGRA assays IFN- IGRA assays were performed using X.DOT-TB kits (TB Healthcare, Foshan, China) according to the manufacturer's instructions 8 .

Analyses were performed using R (version 3.6.1). The normality of data distributions was assessed using the Kolmogorov-Smirnov test. Normally-distributed data are presented as means (SD), while non-normally distributed data are presented as medians (IQR), and categorical variables as frequencies (%). Differences between groups were analysed by Fisher's exact test or Pearson's chisquared test (for categorical data), and Students' t-tests or Mann-Whitney tests (for continuous data).

Among the 36 confirmed COVID-19 patients from Shenyang, Liaoning province, China, included in this study, the most common symptoms at presentation were cough (61.11%), dyspnea (33.33%), is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To evaluate the implications of MTB infection history on the incidence and progression of COVID-19 disease, we addressed three questions. Does MTB co-infection: 1. increase susceptibility to SARS-COV-19 infection; 2. increase disease severity; and 3. lead to more rapid disease progression? We first assigned cases into two groups based on the severity of their COVID-19 pneumonia according to the Diagnostic and Treatment Guidelines of the National Health Commission of China (v6) 9 . Twenty-seven cases were mild/moderate (75%, Group 1) and nine cases were severe/critical (25%, Group 2) ( Table 2) . We then determined the MTB infection status of each patient by examining their clinical history and by performing X.DOT-TB IGRA assays (Table 1) To determine if MTB infection is a risk factor specific for COVID-19 pneumonia, or for pneumonia in general, we compared the MTB infection rate within these COVID-19 cases with data from a case-series comprised of 115 bacterial pneumonia and 62 viral pneumonia patients obtained from another study conducted in Shenyang (unpublished) ( Figure 1A ); MTB infection rates were considerably higher among COVID-19 patients than among bacterial pneumonia patients (36.11% vs 20%; p = 0.047 Figure 1A ) and viral pneumonia patients (36.11% vs 16.13%; p = 0.024),

suggesting that MTB infection status is a specific risk factor for SARS-COV-2 infection rather than for pneumonia in general. The rate of MTB infection in the bacterial and other viral pneumonia is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 16, 2020. . https://doi.org/10.1101/2020.03.10.20033795 doi: medRxiv preprint patients was not significantly different and was approximately the same as that in the general population 10 . The percentage of patients with MTB infection was also considerably higher than the percentage of patients with other co-morbidities (diabetes: 25%; hypertension: 22.2%; coronary heart disease: 8.33%; COPD: 5.56%; Table 1 ), suggesting MTB infection represents a higher risk for SARS-CoV-2 infection.

With respect to disease severity, the percentage of severe/critical cases with MTB coinfection was significantly higher than that in the mild/moderate group (78% vs 22%; p = 0.0049; Figure 1B ). Seven of the 9 severe/critical cases were IGRA+ve indicating MTB co-infection, and of these, 4 of the 5 cases that developed ARDS were IGRA+ve. By comparison, 21 of 27 cases (78%) in Group 1 (mild/moderate cases) were IGRA-ve and had no history of TB disease. This data infers that coinfection of SARS-CoV-2 with MTB tends to lead to the development of more severe or critical COVID-19 symptoms.

Our data also show that MTB infection is associated with more rapid development of symptoms ( Figure 1C -D); MTB coinfected COVID-19 cases developed symptoms on average 3.3 days earlier than their non-MTB-infected counterparts. Development of critical symptoms is reported to occur on average 9 days after initial symptom onset 4 . The 7 MTB-infected severe/critical COVID-19 cases here, however, were categorized as severe/critical 3.4 days after initial symptom development. While the number of cases here is not sufficient to draw a solid conclusion, it would appear that COVID-19 disease progresses more rapidly in the presence of MTB coinfection.

This observational study of the relationship between MTB infection and COVID-19 pneumonia suggests that individuals with latent or active TB may be more susceptible to SARS-CoV-2 infection, and that COVID-19 disease progression may be more rapid and severe. Given that TB causes more deaths than any other infectious disease (1.45 million deaths and 10 million new cases is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 16, 2020. . https://doi.org/10.1101/2020.03.10.20033795 doi: medRxiv preprint in 2018 11 ), and that global rates of LTBI are estimated to be as high as 25% 11 , these findings are a cautionary reminder to clinicians that MTB infection status should be considered when treating COVID-19 patients in order to prevent rapid deterioration in patient health.

Our data suggest that MTB infection could be a more important risk factor than the comorbidities commonly reported in epidemiological studies such as diabetes and hypertension 12 .

COVID-19 and TB are both respiratory diseases. It is perhaps not surprising that chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), and indeed active TB, could predispose susceptibility to SARS-CoV-2. Statistics from other reported studies, however, suggest that the frequency of these co-morbidities is much lower than that of MTB infection in this study is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 16, 2020. . https://doi.org/10.1101/2020.03.10.20033795 doi: medRxiv preprint This is the first study to date to consider MTB infection as a comorbidity for COVID-19.

Going forward, it will be important to validate the relationship uncovered here among these 36 COVID-19 cases in a larger study.

We would like to thank all healthcare professionals involved in the treatment and management of the COVID-19 patients in this study for their dedication and commitment. We would like to acknowledge Dr Juanjuan Zhang, MD (Shenyang Fourth People's Hospital) for coordinating the four COVID-19 cases in the cohort from Shenyang Fourth People's Hospital. We also thank BC-BIO Biotechnology (Guangdong, China) for help with data analysis.

Funding for this work was from the Shenyang Major Science and Technology Innovation R&D Program (JY2020-9-018 to Y. Chen), and the National Science and Technology Major Projects 

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

The authors declare no conflicts of interest. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Comparisons between groups were made using Fisher's exact test (n<40; p0.05), or the Mann-Whitney test (n>40; p0.05).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Data: mean ± SD or n. *Significance of differences between groups.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 16, 2020. . https://doi.org/10.1101/2020.03.10.20033795 doi: medRxiv preprint

Coronavirus disease 2019

Coronavirus disease 2019

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Positive RT-PCR Test Results in Patients Recovered From COVID-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China